NeuBase Therapeutics

32 articles with NeuBase Therapeutics

• NeuBase Presents New Preclinical Data at ASGCT 2022 for Its DM1 Program Demonstrating Wide Tissue Distribution and Supporting a Differentiated Whole-Body Treatment Solution

  5/17/2022

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced the presentation of preclinical pharmacokinetics (PK) and biodistribution data for its lead development candidate, NT-0231.

• 

  Dyne, NeuBase, Graphite and More Present Programs at ASGCT

  5/17/2022

  The ASGCT's 25th Annual Meeting features the latest scientific research in genetics and cellular therapies. Read on for highlights from the meeting.

• NeuBase Therapeutics Reports Business Update and Financial Results for the Second Quarter of Fiscal Year 2022

  5/12/2022

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the three-month period ended March 31, 2022, and other recent developments.

• NeuBase Therapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting

  5/2/2022

  NeuBase Therapeutics, Inc. announced two abstracts have been accepted for presentation at the American Society of Gene and Cell Therapy 25th Annual Meeting, taking place virtually and in person in Washington, D.C., May 16-19, 2022.

• NeuBase Therapeutics Presents New Preclinical Data at MDA 2022 for Its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution, and Myotonia Reversal

  3/13/2022

  NeuBase Therapeutics, Inc., a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced new preclinical data for its lead development candidate, NT-0231.F, to treat myotonic dystrophy type 1.

• NeuBase to Present at Oppenheimer’s 32nd Annual Healthcare Conference

  3/7/2022

  NeuBase Therapeutics, Inc. announced today that company management will participate in a fireside chat and will be available for one-on-one meetings at Oppenheimer’s 32nd Annual Healthcare Conference being held virtually March 15 – 17, 2022.

• NeuBase Therapeutics to Present New Preclinical Data for Myotonic Dystrophy Type 1 Program at the 2022 MDA Clinical & Scientific Conference

  2/28/2022

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced that new preclinical data from its myotonic dystrophy type 1 (DM1) program will be featured in presentations at the 2022 MDA Clinical & Scientific Conference.

• NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2022

  2/10/2022

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the three-month period ended December 31, 2021, and other recent developments.

• 

  BioSpace Movers & Shakers, Jan. 14

  1/14/2022

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• NeuBase Therapeutics Appoints Todd P. Branning Chief Financial Officer

  1/10/2022

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today the appointment of Todd P. Branning as Chief Financial Officer (CFO).

• NeuBase Therapeutics Appoints Dr. Eric J. Ende to Board of Directors

  1/5/2022

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today the appointment of Eric J. Ende, M.D., to the Company's Board of Directors.

• NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2021

  12/23/2021

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the fiscal year ended September 30, 2021, and other recent developments.

• NeuBase to Present at the Jefferies London Healthcare Conference - Nov 03, 2021

  11/3/2021

  NeuBase Therapeutics, Inc., a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present in person a corporate overview at the Jefferies London Healthcare Conference being held November 16 - 18.

• NeuBase to Participate at the Chardan 5th Annual Genetic Medicines Conference

  9/28/2021

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will participate in a fireside chat at the virtual Chardan 5th Annual Genetic Medicines Conference.

• NeuBase to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit 

  9/15/2021

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held September 20 – 23.

• NeuBase Therapeutics Appoints Anthony Rossomando, Ph.D. as Chief Technology Officer

  9/14/2021

  NeuBase Therapeutics, Inc., a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced the appointment of Anthony Rossomando, Ph.D., as Chief Technology Officer.

• NeuBase Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investment Conference

  9/1/2021

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the virtual H.C. Wainwright 23rd Annual Global Investment Conference.

• NeuBase Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2021 and Recent Operating Highlights

  8/12/2021

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the three- and nine-month periods ended June 30, 2021.

• NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibition of KRAS Mutations to Inhibit Tumor Growth

  6/8/2021

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of precision genetic medicines, today announced positive new data and program updates for its development pipeline of PATrOL-enabled genetic medicines.

• NeuBase Therapeutics Announces Speakers for Virtual R&D Day Taking Place on June 8th

  6/2/2021

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of precision genetic medicines, today announced that it will host a virtual R&D day for investors and analysts on Tuesday, June 8, 2021 at 12:30 p.m. EDT.